PanGen Biotech Inc. (KOSDAQ:222110)
South Korea · Delayed Price · Currency is KRW 4,960.00
-150.00 (-2.94%)
At close: Apr 2, 2026
PanGen Biotech Revenue
In the year 2025, PanGen Biotech had annual revenue of 13.42B KRW, down -8.56%. PanGen Biotech had revenue of 2.48B in the quarter ending December 31, 2025, a decrease of -42.86%.
Revenue
13.42B
Revenue Growth
-8.56%
P/S Ratio
5.14
Revenue / Employee
n/a
Employees
n/a
Market Cap
68.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.42B | -1.26B | -8.56% |
| Dec 31, 2024 | 14.67B | 7.36B | 100.58% |
| Dec 31, 2023 | 7.32B | 814.47M | 12.53% |
| Dec 31, 2022 | 6.50B | -1.43B | -18.08% |
| Dec 31, 2021 | 7.94B | 1.74B | 28.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 123.77B |
| Choong Ang Vaccine Laboratory | 39.19B |
| Naturalendo Tech | 22.23B |
| Ark Solutions | 16.08B |
| HLB Pep | 4.96B |
| EyeGene | 3.57B |
| SunBio,Inc. | 2.17B |
| Aptamer Sciences | 1.08B |